Supplement labeling
This article was originally published in The Tan Sheet
Executive Summary
New York Senate bill (SB 4909) would require all dietary supplements to contain a statement in their labeling "clearly discernible to a customer" disclosing whether "the product has or has not been tested by [FDA]." The statement would accompany the FDA disclaimer regarding structure/function claims required under the Dietary Supplement Health & Education Act. The bill was introduced in the Senate April 20 and has been referred to the Committee on Consumer Protection
You may also be interested in...
Ephedra Litigation Could Threaten AER Preemption Provision – CRN’s Mister
A court order overturning FDA's ban of ephedra could impact industry's ability to get federal preemption into a mandatory AER bill, Council for Responsible Nutrition President Steve Mister stated at the SupplySide East trade show and conference in Secaucus, N.J. May 3
Ephedra Litigation Could Threaten AER Preemption Provision – CRN’s Mister
A court order overturning FDA's ban of ephedra could impact industry's ability to get federal preemption into a mandatory AER bill, Council for Responsible Nutrition President Steve Mister stated at the SupplySide East trade show and conference in Secaucus, N.J. May 3
Ephedra Litigation Could Threaten AER Preemption Provision – CRN’s Mister
A court order overturning FDA's ban of ephedra could impact industry's ability to get federal preemption into a mandatory AER bill, Council for Responsible Nutrition President Steve Mister stated at the SupplySide East trade show and conference in Secaucus, N.J. May 3